Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01563679 · ClinicalTrials.gov registry record
Analysis of Percutaneous Ablations for Cancer Treatment
A clinical trial, sponsored by Emory University.
- Completed
- Registry status
- 26
- Enrollment target
NCT01563679: Completed study, sponsored by Emory University.
NCT01563679 is a clinical trial that has completed, run by Emory University. The registered enrollment target is 26 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01563679 has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- 26 participants
- Enrollment target
Study Summary
This is a study involving patients with cancer who are referred by their treating physician for percutaneous locoregional therapies. Patient's clinical and radiology findings, pathology findings, survival, treatment responses, and complications after their locoregional therapy will be studied.
Primary Outcome
Patients will complete the QOL questionnare during their follow up visits after procedure. 1 month, 3 months, 6 months and 1 year.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2012-02 |
| Est. Completion | 2014-01 |
What the finished NCT01563679 record still lists
NCT01563679 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 26 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01563679 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01563679 about?
NCT01563679 is a clinical study titled "Analysis of Percutaneous Ablations for Cancer Treatment". This is a study involving patients with cancer who are referred by their treating physician for percutaneous locoregional therapies. Patient's clinical and radiology findings, pathology findings, survival, treatment responses, and complications after their locoregional therapy will be studied.
What is the current status of trial NCT01563679?
This trial is currently completed. The enrollment target is 26 participants. The study started on 2012-02. Estimated completion is 2014-01.
Who is sponsoring clinical trial NCT01563679?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia